These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 21232669

  • 1. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G, AVRO Investigators.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):313-21. PubMed ID: 21232669
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG, Roos JS, Kavanagh KM, Dickinson G.
    Am Heart J; 2010 Jun 18; 159(6):1095-101. PubMed ID: 20569725
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 18; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 18; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ, Atrial Arrhythmia Conversion Trial Investigators.
    Circulation; 2008 Mar 25; 117(12):1518-25. PubMed ID: 18332267
    [Abstract] [Full Text] [Related]

  • 14. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.
    Conde D, Costabel JP, Aragon M, Lambardi F, Klein A, Corrales Barbosa A, Trivi M, Giniger A.
    Cardiovasc Ther; 2013 Dec 25; 31(6):377-80. PubMed ID: 23683253
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P, Gilligan P, Mahon P, Sheahan R.
    Ir J Med Sci; 2017 Nov 25; 186(4):903-908. PubMed ID: 28168639
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
    Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN.
    Int J Cardiol; 2013 Jun 05; 166(1):147-51. PubMed ID: 22108512
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.